Analysis demonstrates a prognostic gene signature predicts survival in pancreatic adenocarcinoma, suggesting immunotherapy strategies may be required.
Pancreatic adenocarcinoma (PAAD) has a poor prognosis and responds poorly to immunotherapy. Growing evidence indicates that autophagy promotes tumor progression, and autophagy-related genes (ARGs) have been established as prognostic markers in various cancers. Based on consensus clustering of ARGs, 177 PAAD cases were classified into two subtypes, with cluster B exhibiting weaker anti-tumor immunity. Using univariate COX and Least absolute shrinkage and selection operator (LASSO) regression, 13 ARGs were identified to construct a prognostic model. A risk score formula was developed and validated using the GSE183795 dataset. Patients were divided into high- and low-risk groups, with the high-risk group associated with poorer survival. The model showed strong predictive accuracy, with time-dependent area under the curve (AUC) values ranging from 0.762 to 0.848 in the training cohort and 0.658 to 0.714 in the validation cohort. Further analysis revealed that high-risk patients had suppressed immunity but increased sensitivity to certain chemotherapy drugs. Additionally, high tumor mutational burden (TMB) and RNA stemness score (RNAss) were correlated with worse prognosis in high-risk patients. This ARG-based model effectively predicts PAAD outcomes and may guide clinical treatment strategies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: